Companies
Genvax Technologies
Animal mRNA vaccines — self-amplifying mRNA (saRNA).
- Country
- United States
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| livestock-aqua | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisemaefsanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Production site | 10,000-square-foot manufacturing facility located at the Iowa State University Research Park in Ames, Iowa | econdev.iastate.edu |
| Headcount | approximately 8 to 10 employees as of mid-2026 medium confidence | aeroleads.com · greyb.com |
| Revenue | estimated annual revenue in the range of $1 million to $10 million as of mid-2026 medium confidence | greyb.com |
| Regulatory approval | the company has made initial submissions to the USDA for product approvals, with the first product expected to launch in 2027 medium confidence | cultivationcorridor.org |
| Certification | registered as a for-profit manufacturer of goods in the United States; primary NAICS code 325414 (Biological Product Manufacturing) | highergov.com |
Independent sources: aeroleads.com · cultivationcorridor.org · econdev.iastate.edu · greyb.com · highergov.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Veterinary biotech & mRNA veterinary drugs | livestock-aqua | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.